$9.23
▲ +$0.39
(+4.41%)
Vol 288K
Mkt Cap
$2.4B
P/E
13.0
ROE
25.5%
Margin
3.0%
Beta
0.95
Div Yield
0.86%
52W
$6–$13
Wall Street Consensus
16 analysts · Apr 20260
Strong Buy
1
Buy
6
Hold
8
Sell
1
Strong Sell
6.2%
Buy Rating
Price Chart
Similar Stocks
PBH
Prestige Consumer Healthcare Inc
P/E 14.5
$2.7B
ELVN
Enliven Therapeutics Inc
$913.9M
TARS
Tarsus Pharmaceuticals Inc
$3.5B
MANE
Veradermics Inc
$2.6B
AMRX
Amneal Pharmaceuticals Inc
P/E 671.4
$4.0B
DFTX
Definium Therapeutics Inc
PAHC
Phibro Animal Health Corp
P/E 22.4
$1.5B
OCUL
Ocular Therapeutix Inc
$2.6B
LLY
Eli Lilly and Co
P/E 42.1
$869.2B
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $0.73 | $0.63 | $-0.10 |
| Sep 2025 | $0.95 | $1.01 | +$0.06 |
| Jun 2025 | $0.96 | $1.00 | +$0.04 |
| Mar 2025 | $0.91 | $1.02 | +$0.11 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $1.6B | $1.5B | $1.6B | $1.6B | $1.5B |
| Net Income | — | $109.0M | $87.0M | $145.0M | $160.0M | -$205.0M |
Fundamentals Trend
| Metric | 2026-04-12 | 2026-04-17 |
|---|---|---|
| ROE (TTM) | 25.5% | 25.5% |
| P/E (TTM) | 12.29 | 12.99 |
| Net Margin | 3.0% | 3.0% |
| Gross Margin | 53.3% | 53.3% |
| D/E Ratio | — | — |
| Current Ratio | 1.82 | 1.82 |
Key Ratios
ROA (TTM)
1.4%
P/S (TTM)
0.39
P/B
2.5
EPS (TTM)
$0.72
CF/Share
$3.18
Rev Growth 3Y
+0.2%
52W High
$13.25
52W Low
$5.69
$5.69
52-Week Range
$13.25
Financial Health
Free Cash Flow
$76.0M
Net Debt
$8.1B
Cash
$574.0M
Total Debt
$8.6B
As of Dec 31, 2025
How does OGN compare to Pharmaceuticals peers?
Peer group: Peers · Pharmaceuticals (Peers) · 10 companies
OGN valuation vs Pharmaceuticals peers
P/E ratio
13.0
▼
54%
below
peers
(28.3)
vs Peers
vs Industry
Undervalued
P/S ratio
0.4
▼
88%
below
peers
(3.3)
vs Peers
vs Industry
Undervalued
P/B ratio
2.5
▼
30%
below
peers
(3.6)
vs Peers
vs Industry
Pricier
Div yield
0.9%
▲
6%
above
peers
(0.8%)
vs Peers
vs Industry
Low yield
OGN profitability vs Pharmaceuticals peers
ROE
25.5%
▲
202%
above
peers
(-24.9%)
vs Peers
vs Industry
Top tier
Net margin
3.0%
▲
88%
above
peers
(1.6%)
vs Peers
vs Industry
Weak
Gross margin
53.3%
▼
23%
below
peers
(69.6%)
vs Peers
vs Industry
Weak
ROA
1.4%
▲
201%
above
peers
(-1.4%)
vs Peers
vs Industry
Below avg
OGN financial health vs Pharmaceuticals peers
D/E ratio
—
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
1.8
▼
51%
below
peers
(3.7)
vs Peers
vs Industry
Low liquidity
Beta
1.0
▲
107%
above
peers
(0.5)
vs Peers
vs Industry
More volatile
OGN fundamentals radar
OGN
Peer median
Industry
OGN profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
OGN vs peers: key metrics
Dividends
$0.08
/ year
Feb 23, 2026
$0.0200
Nov 20, 2025
$0.0200
Aug 15, 2025
$0.0200
May 12, 2025
$0.0200
Feb 24, 2025
$0.2800
Nov 12, 2024
$0.2800
Aug 16, 2024
$0.2800
May 10, 2024
$0.2800